Australia Freeze-Drying Equipment Market Projected to Reach USD 124.8 Million by 2034

Australia Freeze-Drying Equipment Market Overview:
Australia's freeze-drying equipment market is experiencing robust growth, propelled by expanding pharmaceutical manufacturing investments, surging demand for freeze-dried food products, growing biotechnology research activity, and the country's strategic push to build sovereign capability in vaccine and biologic production. The Australia freeze-drying equipment market size reached USD 72.5 Million in 2025. Looking forward, the market is projected to reach USD 124.8 Million by 2034, exhibiting a growth rate (CAGR) of 5.91% during 2026-2034. The market spans tray style, manifold, and rotary freeze dryers operating at industrial, pilot, and laboratory scales, serving applications across food processing and packaging, pharmaceutical and biotechnology, biomedical engineering, and other sectors. Pfizer's AUD $150 million Melbourne facility upgrade with lyophilization capability, CSL's $1 billion vaccine manufacturing facility, Australia's total exports reaching USD 27.9 billion in December 2024, the growing freeze-dried food market, and advances in AI-assisted process optimization are among the key factors driving market expansion.

Read more about Australia Freeze-Drying Equipment Market
https://www.imarcgroup.com/australia-freeze-drying-equipment-market

Australia Freeze-Drying Equipment Market Summary:
• Pharmaceutical and biotechnology applications account for approximately 40% of global freeze-drying equipment demand, with about 50% of biopharmaceuticals currently available in the market being lyophilized. Australia's pharmaceutical market, projected to reach USD 31.1 billion by 2033, is driving growing demand for industrial-scale lyophilization systems that maintain the stability and efficacy of vaccines, biologics, monoclonal antibodies, and injectable medications.

• Pfizer committed AUD $150 million (USD $98 million) to upgrade its Melbourne manufacturing facility, adding a fifth filling line equipped with robotics and AI technology, creating 500 new jobs. The upgraded site, which commenced commercial manufacture in 2026, produces medicines exported to over 60 countries and treats up to 15 million patients annually, with lyophilization capability supporting antimicrobial, oncology, and anaesthetic product lines.

• CSL Seqirus opened its state-of-the-art $1 billion cell-based influenza vaccine and antivenom manufacturing facility in Melbourne in December 2025, making Australia one of only three countries globally with end-to-end capability to manufacture advanced cell-based influenza vaccines. This investment directly drives demand for pharmaceutical-grade freeze-drying equipment to support vaccine stabilization and long-term storage.

• Food processing and packaging is forecast to represent approximately 44.66% of the total market, driven by growing consumer demand for nutritious, convenient, and shelf-stable food products. Australia's freeze-dried food market is projected to grow at over 6.5% annually, creating sustained demand for industrial-scale tray style and rotary freeze dryers across fruit, vegetable, meat, and ready-to-eat meal categories.

• MedTEC Pharma, based in South Australia, emerged in February 2025 as one of the first Australian companies to manufacture freeze-dried products from locally cultivated plants, investing in advanced post-harvesting technologies including a large-scale freeze dryer from New Zealand and cryo-trimming equipment from the United States, demonstrating the expansion of freeze-drying applications into emerging product categories.

• A domestic freeze-drying firm announced expansion of its Tasmania-based production facility in April 2025 to increase capacity for both domestic and export markets, while a notable Australian brand expanded its freeze-dried vegetable snack range in March 2025 to meet growing demand for nutritious, on-the-go options - both reflecting the strong growth trajectory in food processing applications.

• Australia's total exports reached USD 27.9 billion in December 2024, underscoring the country's export-oriented economy that creates demand for freeze-drying technology to produce shelf-stable, lightweight products suitable for international shipping across pharmaceuticals, food, and biotechnology sectors.

• Technology innovation is accelerating across the industry, with GEA Group unveiling energy-efficient freeze-dryer models with heat recovery systems in October 2024, Mitsubishi Electric developing AI-assisted process optimization for high-value biotech products in June 2025, and SP Scientific expanding its freeze dryer portfolio in December 2025 to support large-scale biopharmaceutical manufacturing for vaccine and biologics production.

Request a Business Sample Report for Procurement & Investment Evaluation: https://www.imarcgroup.com/australia-freeze-drying-equipment-market/requestsample

Key Trends Shaping the Australia Freeze-Drying Equipment Market:
• Pharmaceutical manufacturing expansion driving industrial lyophilization demand: Australia's pharmaceutical sector is experiencing a transformative investment cycle that directly drives freeze-drying equipment demand. Pfizer's AUD $150 million Melbourne upgrade with AI and robotics, CSL's $1 billion vaccine manufacturing facility, and the broader pharmaceutical market projected at USD 31.1 billion are creating sustained demand for industrial-scale lyophilizers. With approximately 50% of biopharmaceuticals being lyophilized and growing focus on onshore vaccine production capability, pharmaceutical applications represent the highest-value segment for freeze-drying equipment suppliers.

• Freeze-dried food market growth creating sustained equipment demand: Food processing accounts for approximately 44.66% of total market demand and represents the fastest-growing application segment. Australia's freeze-dried food market is expanding at over 6.5% annually, driven by consumer preferences for convenient, nutritious, and shelf-stable products. The expansion of production facilities in Tasmania, new freeze-dried vegetable snack ranges, and growing export opportunities for lightweight, shelf-stable Australian food products are fueling continuous demand for industrial tray style and rotary freeze dryers.

• AI and smart technology integration transforming equipment capabilities: The integration of artificial intelligence, advanced SCADA systems, and IoT connectivity into freeze-drying equipment is reshaping the market's technology landscape. Mitsubishi Electric's AI-assisted process optimization for biotech products, Telstar's advanced SCADA integration for real-time monitoring, and Pfizer's robotics-equipped Melbourne facility demonstrate the shift toward smart, automated lyophilization. These technologies improve batch consistency, reduce energy consumption, enhance data integrity for regulatory compliance, and enable predictive maintenance.

• Sovereign manufacturing capability and supply chain resilience: Australia's post-pandemic strategic focus on building domestic manufacturing capability across pharmaceuticals, vaccines, and critical food supply chains is driving investment in onshore freeze-drying capacity. CSL's facility making Australia one of only three countries with end-to-end cell-based vaccine manufacturing, combined with MedTEC Pharma's investment in local freeze-dried product manufacturing, reflects a national priority that will sustain equipment demand over the forecast period.

• Energy efficiency and sustainability in lyophilization technology: Freeze-drying is an energy-intensive process, and manufacturers are responding with next-generation equipment featuring heat recovery systems, improved vacuum efficiency, and optimized cycle programming. GEA Group's energy-efficient models unveiled in October 2024 and the broader industry push toward sustainable manufacturing align with Australia's corporate ESG commitments and rising energy costs, making energy-efficient equipment a key purchasing criterion for both food and pharmaceutical processors.

Market Growth Drivers:
Pharmaceutical and Biotechnology Manufacturing Investment
Australia's freeze-drying equipment market is being powerfully driven by a historic wave of investment in pharmaceutical and biotechnology manufacturing infrastructure. Pfizer's AUD $150 million upgrade of its Melbourne facility - adding a fifth filling line with robotics and AI technology, creating 500 jobs, and commencing commercial production in 2026 - represents a significant expansion of lyophilization-dependent manufacturing capacity. The site produces medicines exported to more than 60 countries, treating up to 15 million patients annually across antimicrobial, oncology, anaesthetic, and anti-inflammatory product lines. CSL Seqirus's opening of its $1 billion cell-based influenza vaccine and antivenom manufacturing facility in Melbourne in December 2025 further amplifies demand, making Australia one of only three countries globally with end-to-end cell-based vaccine manufacturing capability. With approximately 50% of biopharmaceuticals being lyophilized and pharmaceuticals accounting for 40% of global freeze-drying equipment demand, Australia's pharmaceutical market - projected at USD 31.1 billion by 2033 - creates an enormous and growing addressable market. The focus on biologics, monoclonal antibodies, and vaccine production, all of which require lyophilization for stability and long-term storage, ensures that pharmaceutical-grade freeze-drying equipment remains the highest-value segment of the Australian market.

Freeze-Dried Food Market Expansion and Export Growth
The food processing and packaging segment, accounting for approximately 44.66% of total market demand, represents the largest single application for freeze-drying equipment in Australia. The country's freeze-dried food market is growing at over 6.5% annually, driven by consumer demand for convenient, nutritious, lightweight, and shelf-stable products across categories including fruits, vegetables, meats, dairy, and complete ready-to-eat meals. This growth is being fueled by multiple converging trends: the expansion of domestic production capacity, with a Tasmania-based freeze-drying firm announcing facility expansion in April 2025; new product innovation, with brands launching freeze-dried vegetable snack ranges in March 2025; and growing export opportunities leveraging Australia's reputation for clean, high-quality food products. With total exports reaching USD 27.9 billion in December 2024, Australia's export-oriented economy creates strong demand for freeze-drying technology that produces products ideally suited for international distribution - lightweight, shelf-stable, and requiring no refrigeration. The outdoor recreation, emergency preparedness, and military rations markets provide additional demand channels. MedTEC Pharma's investment in large-scale freeze-drying equipment from New Zealand for processing locally cultivated plants demonstrates the expansion of food-grade lyophilization into emerging product categories, further broadening the equipment market's addressable opportunity.

Technology Innovation, Laboratory Research, and Biomedical Applications
The convergence of technology innovation and expanding research activity is creating significant growth across pilot-scale and laboratory-scale freeze-drying equipment segments. Australia's robust university research ecosystem, CSIRO laboratories, and growing network of biotech startups all require sophisticated lyophilization equipment for drug development, formulation studies, and biological sample preservation. The technology landscape is advancing rapidly, with AI-assisted process optimization (Mitsubishi Electric, June 2025) enabling precise control of freeze-drying parameters for high-value biotech products, advanced SCADA systems (Telstar, January 2024) providing real-time monitoring and data integrity for regulatory compliance, and energy-efficient designs with heat recovery systems (GEA Group, October 2024) reducing operational costs. SP Scientific's December 2025 expansion of its freeze dryer portfolio for large-scale biopharmaceutical manufacturing and Millrock Technology's launch of advanced laboratory freeze-dryers with improved process control demonstrate the continuous innovation cycle driving equipment upgrades and replacements. Controlled nucleation technology and continuous freeze-drying processes are transforming efficiency, scalability, and reproducibility, making lyophilization accessible for a wider range of applications. Biomedical engineering applications - including tissue preservation, diagnostic reagent stabilization, and biological sample banking - represent a growing niche that requires precision laboratory equipment with exacting temperature and vacuum control capabilities.

Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the Australia freeze-drying equipment market, along with forecasts at the country and regional levels from 2026-2034. The market has been categorized based on dryer type, scale of operation, application, and region.
By Dryer Type:
• Tray Style Freeze Dryers
• Manifold Freeze Dryers
• Rotary Freeze Dryers

By Scale of Operation:
• Industrial Scale Freeze Dryer
• Pilot Scale Freeze Dryer
• Laboratory Scale Freeze Dryer

By Application:
• Food Processing and Packaging
• Pharmaceutical and Biotechnology
• Biomedical Engineering
• Others

By Region:
• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia

Key Players:
The Australia freeze-drying equipment market features a competitive landscape dominated by global technology leaders and specialist manufacturers serving pharmaceutical, food, and research sectors. GEA Group is a leading player, unveiling energy-efficient freeze-dryer models with heat recovery systems and strengthening its regional presence with customized solutions for Australian food processors in January 2026. SP Scientific (SP Industries) expanded its freeze dryer portfolio in December 2025 to support large-scale biopharmaceutical manufacturing and secured major contracts for vaccine and biologics preservation. Azbil Telstar integrated advanced SCADA systems into its industrial lyophilizers for enhanced real-time monitoring and biopharma data integrity. Other key global players include Millrock Technology (launching advanced laboratory freeze-dryers in December 2025), Labconco, Tofflon Science and Technology, and Yamato Scientific (upgrading laboratory freeze dryers with advanced vacuum control in August 2025). Aus Freeze Dry represents the domestic Australian manufacturing segment. The market research report provides a comprehensive analysis of the competitive landscape including key player positioning, market structure, top winning strategies, competitive dashboards, and detailed company profiles.

Key Aspects Required for the Australia Freeze-Drying Equipment Market:
• End-use demand spans pharmaceutical manufacturers (Pfizer's AUD $150 million Melbourne facility, CSL's $1 billion vaccine plant), food processors (freeze-dried food market growing at 6.5%+ annually), biotechnology companies, biomedical research laboratories, university research facilities, and CSIRO laboratories - with pharmaceuticals and food processing together accounting for approximately 85% of total equipment demand.

• Tray style freeze dryers dominate the industrial segment for large-batch food and pharmaceutical processing, while manifold freeze dryers serve laboratory and small-batch applications, and rotary freeze dryers offer specialized solutions for uniform drying of granular or particulate materials.

• The pharmaceutical growth driver is anchored by the fact that approximately 50% of biopharmaceuticals are lyophilized, with Australia's pharmaceutical market projected at USD 31.1 billion by 2033. Pfizer's facility producing medicines for 15 million patients annually across 60+ countries and CSL's unique Southern Hemisphere cell-based vaccine capability create high-value equipment demand.

• Food processing applications account for approximately 44.66% of total demand, driven by consumer preferences for convenient, nutritious, shelf-stable products. Facility expansions in Tasmania, new product launches in freeze-dried snacks, and Australia's USD 27.9 billion export economy create sustained demand for industrial-scale food lyophilization equipment.

• Technology innovation is a key competitive differentiator, with AI-assisted process optimization, advanced SCADA integration, energy-efficient heat recovery systems, controlled nucleation, and continuous freeze-drying processes driving equipment upgrades and creating premium product categories across all scales of operation.

• Distribution channels include direct sales from global manufacturers to major pharmaceutical and food companies, specialized scientific equipment distributors serving laboratory and pilot-scale markets, and regional representatives providing installation, training, and after-sales service across Australia's geographically dispersed industrial and research centers.

• Sovereign manufacturing capability is a strategic market driver, with post-pandemic policy priorities focusing on onshore pharmaceutical production, vaccine manufacturing self-sufficiency, and domestic food processing capacity - all of which require investment in freeze-drying infrastructure.

• Victoria & Tasmania and ACT & New South Wales lead regional demand, reflecting the concentration of pharmaceutical manufacturing (Pfizer Melbourne, CSL Melbourne), biotechnology research, and food processing facilities in Melbourne, Sydney, and their surrounding industrial corridors.

Recent News and Developments:
January 2026: GEA Group strengthened its regional presence with customized freeze-drying solutions for Australian food processors, capitalizing on rising demand for premium preserved fruits, vegetables, and ready-to-eat meals in both domestic and export markets.

December 2025: CSL Seqirus opened its state-of-the-art $1 billion cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, making Australia one of only three countries globally with end-to-end capability to manufacture advanced cell-based influenza vaccines, driving demand for pharmaceutical-grade lyophilization equipment.

December 2025: SP Scientific expanded its freeze dryer portfolio to support large-scale biopharmaceutical manufacturing, addressing growing global demand from vaccine and biologics production, with significant implications for Australia's expanding pharmaceutical sector.

December 2025: Millrock Technology launched a new line of advanced laboratory freeze-dryers with improved process control and energy efficiency, targeting pharmaceutical research and biotech development applications.

August 2025: Yamato Scientific upgraded its laboratory freeze dryers with advanced vacuum control systems for sensitive sample preservation, enhancing capabilities for Australia's growing biotechnology and biomedical research sectors.

June 2025: Mitsubishi Electric developed freeze dryers with AI-assisted process optimization specifically designed for high-value biotechnology products, representing a significant advance in smart lyophilization technology.

April 2025: A domestic Australian freeze-drying firm announced expansion of its Tasmania-based production facility to increase capacity for both domestic and export markets, responding to growing demand for freeze-dried food products.

February 2025: MedTEC Pharma, based in South Australia, emerged as one of the first Australian companies to manufacture freeze-dried products from locally cultivated plants, investing in a large-scale freeze dryer from New Zealand and advanced post-harvesting technologies from the United States.

Note: If you require any specific information not currently covered within the scope of the report, IMARC Group will provide it as part of customization.
Speak to an analyst:
https://www.imarcgroup.com/request?type=report&id=32322&flag=E

Contact Us
IMARC Group
134 N 4th St., Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel. No.: (D) +91 120 433 0800
United States: +1-201-971-6302

About Us
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.